Table 2

Number of patients experiencing side effects during TNFi treatment

AdalimumabInfliximabTotal
Infusion-related reaction
 Mild0 (0)6 (18)6 (14)
 Severe0 (0)3 (9)3 (7)
Anaphylaxis
 Anaphylaxis0 (0)1 (3)1 (2)
Infection
 Respiratory1 (11)3 (9)4 (9)
 Abscesses0 (0)1 (3)1 (2)
 Miliary tuberculosis0 (0)1 (3)1 (2)
 Cellulitis with septicaemia0 (0)1 (3)1 (2)
Neoplasia
 Non-Hodgkin’s lymphoma1 (11)0 (0)1 (2)
Cutaneous
 Injection site cutaneous1 (11)0 (0)1 (2)
 Psoriasis0 (0)1 (3)1 (2)
 Alopecia1 (11)0 (0)1 (2)
 Other rash0 (0)4 (12)4 (9)
Other
 Lupus0 (0)2 (6)2 (5)
 Myalgia2 (22)0 (0)2 (5)
 Fatigue1 (11)3 (9)4 (9)
 Headache2 (22)0 (0)2 (5)
 Arthralgia2 (22)1 (3)3 (7)
 Back pain0 (0)1 (3)1 (2)
 Nausea2 (22)0 (0)2 (5)
 Haematuria1 (11)0 (0)1 (2)
 Night sweats1 (11)0 (0)1 (2)
 Gout1 (11)0 (0)1 (2)
 Mood disturbance1 (11)0 (0)1 (2)
Total172845
  • Percentage proportions are shown in brackets.

  • TNFi, tumour necrosis factor-alpha inhibitor.